AbbVie has selected North Carolina as the site for a new $1.4 billion manufacturing campus that will integrate artificial intelligence with advanced production and laboratory technologies to support its immunology, neuroscience, and oncology medicine lines. No timeline for completion was announced. The investment reflects both the scale of AbbVie’s pipeline ambitions and a broader pharmaceutical industry trend toward AI-assisted manufacturing—applying machine learning to process optimization, quality control, and yield prediction in ways that reduce variability and regulatory risk.

Eli Lilly has announced a deal to acquire Kelonia Therapeutics, gaining access to KLN-1010, a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 trials for relapsed or refractory multiple myeloma, with data recently featured at the 2025 ASH Annual Meeting plenary session. The acquisition also brings Kelonia’s in vivo gene delivery and integration platform, which Lilly views as broadly applicable across its genetic medicine programs. The distinction between in vivo and ex vivo CAR-T is significant.

Northwest Biotherapeutics has established a dedicated leukapheresis clinic at The London Welbeck Hospital, designed to process up to four patients per day with capacity for extended hours and weekend operations as demand scales. The facility is intended to support the company’s cell therapy pipeline by bringing the collection process in-house. Leukapheresis—the extraction of white blood cells from a patient’s blood for use in manufacturing personalized immunotherapies—has long been a logistical bottleneck in the cell therapy supply chain.